RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFα or anti-IL-1 therapies

Citations Over TimeTop 10% of 2009 papers

Abstract

Anti-TNFalpha or anti-IL-1 therapy inhibited parameters of local and systemic inflammation, and partially reduced local but not systemic bone loss in AIA and CIA rats. RANKL inhibition prevented local and systemic bone loss without significantly inhibiting local or systemic inflammatory parameters.

Related Papers

• → Aging effect of osteoprotegerin and receptor activator of nuclear factor-κB ligand expression in human periodontal ligament cells under continuous static pressure.(2022)3 cited
• [Indication of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa B ligand (RANKL) in gingival crevicular fluid to remodeling of alveolar bone during retention].(2012)
• [Expressions of RANK, RANKL, and osteoprotegerin in male rats at different ages].(2011)
• Different expressing levels of osteoprotegerin and receptor activator of nuclear factor-κB ligand from osteoblasts of young, adult and aged mice(2005)
• EFFECTS OF 1α,25(OH)_2D_3 ON THE EXPRESSION OF RECEPTOR ACTIVATOR OF NF-КB LIGAND AND OSTEOPROTEGERIN IN RAT OSTEOBLASTS IN VITRO(2010)